PBI Business Summary

Pharmosa Biopharm Inc. (PBI) is a clinical-stage biotechnology company that specializes in the development of innovative drug-device combination therapies using its proprietary liposome technology. The company generates revenue primarily through strategic licensing agreements, upfront payments, and milestone-based royalties, most notably through its global partnership with Liquidia Corporation for its lead candidate, L606. PBI's primary business segments are centered on its R&D pipeline for rare pulmonary diseases, featuring L606 (liposomal treprostinil) in Phase 3 trials for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and L608 (liposomal iloprost) in Phase 2 development. Within the specialized respiratory market, PBI competes with major players such as United Therapeutics, Liquidia Corporation, and Merck & Co., positioning itself as a niche innovator focused on improving patient tolerability and dosing convenience through sustained-release inhalation technology. The company was founded in 2000 by Dr. Pei Kan, who serves as President and leads the technical direction of the firm. Dr. Kan holds a Ph.D. in Chemical Engineering from National Tsing Hua University and possesses over two decades of expertise in pharmaceutical formulation, including previous leadership tenures at the Industrial Technology Research Institute (ITRI) and Taiwan Liposome Company (TLC). The current leadership team is chaired by Chien-Chih Wang, who also serves as Chairman of Anxo Pharmaceutical, and includes Vice Chairman Lin-Chuan Yan, bringing significant pedigree from the Taiwanese biopharmaceutical industry. PBI is backed by a robust board and notable institutional investors, including CDIB Capital Healthcare Ventures II, Cathay Venture Inc., and the National Development Fund of Taiwan, reflecting strong local and sector-specific financial support.